Answers are grounded in this paper and cite their sources.
Recently FDA-approved drugs for cardiovascular disease (CVD) require robust post-marketing surveillance. The objective of this study was to assess their safety using a large pharmacovigilance database.
No takes yet. Share an insight, caveat, or question.
Park et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: